Dr. Daniel Petrylak on Early Trials for Urothelial Bladder Cancer Treatment
Daniel P. Petrylak, MD, talks about taking the clinical trials examining MPDL3280A a step further for bladder cancer patients.
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, professor and co-director, Signal Transduction Research Program, Yale Cancer Center, talks about taking the clinical trials examining MPDL3280A (antiPD-L1) a step further.
Petrylak says patients with a high level of PD-L1 expression who are treated with the drug often have better responses than those without. Moreover, while MPDL3280A is still in its infancy, the treatment could be evolved into something that may be able to help a wider range of patients in the future, he adds.
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
